Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations

Detalles Bibliográficos
Autores principales: Krawczyk, Paweł, Powrózek, Tomasz, Nicoś, Marcin, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631283/
https://www.ncbi.nlm.nih.gov/pubmed/26557768
http://dx.doi.org/10.5114/wo.2015.52660
_version_ 1782398835401687040
author Krawczyk, Paweł
Powrózek, Tomasz
Nicoś, Marcin
Milanowski, Janusz
author_facet Krawczyk, Paweł
Powrózek, Tomasz
Nicoś, Marcin
Milanowski, Janusz
author_sort Krawczyk, Paweł
collection PubMed
description
format Online
Article
Text
id pubmed-4631283
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-46312832015-11-10 Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations Krawczyk, Paweł Powrózek, Tomasz Nicoś, Marcin Milanowski, Janusz Contemp Oncol (Pozn) Letter to the Editor Termedia Publishing House 2015-07-08 2015 /pmc/articles/PMC4631283/ /pubmed/26557768 http://dx.doi.org/10.5114/wo.2015.52660 Text en Copyright © 2015 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Krawczyk, Paweł
Powrózek, Tomasz
Nicoś, Marcin
Milanowski, Janusz
Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
title Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
title_full Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
title_fullStr Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
title_full_unstemmed Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
title_short Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
title_sort letter to the editor concerning first-line therapy with afatinib – an irreversible egfr tki and overall survival of nsclc patients with egfr gene mutations
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631283/
https://www.ncbi.nlm.nih.gov/pubmed/26557768
http://dx.doi.org/10.5114/wo.2015.52660
work_keys_str_mv AT krawczykpaweł lettertotheeditorconcerningfirstlinetherapywithafatinibanirreversibleegfrtkiandoverallsurvivalofnsclcpatientswithegfrgenemutations
AT powrozektomasz lettertotheeditorconcerningfirstlinetherapywithafatinibanirreversibleegfrtkiandoverallsurvivalofnsclcpatientswithegfrgenemutations
AT nicosmarcin lettertotheeditorconcerningfirstlinetherapywithafatinibanirreversibleegfrtkiandoverallsurvivalofnsclcpatientswithegfrgenemutations
AT milanowskijanusz lettertotheeditorconcerningfirstlinetherapywithafatinibanirreversibleegfrtkiandoverallsurvivalofnsclcpatientswithegfrgenemutations

Ejemplares similares